论文部分内容阅读
目的：比较洛之达（国产洛伐他汀）和辛伐他汀调节血脂代谢紊乱的临床效果。方法：选择原发性血脂代谢紊乱６１例，随机分为洛之达（２０ｍｇ／ｄ）治疗组（３０例）和辛伐他汀（１０ｍｇ／ｄ）对照组（３１例），均治疗６周。结果：与治疗前比，洛之达治疗６周使ＴＣ，ＬＤＬＣ，ＡｐｏＢ分别极显著性下降３５．１％，３７．７％和１５．６％，辛伐他汀组则分别极显著性下降３８．７％，４２．７％和１６．７％。洛之达调节ＴＣ，ＴＧ，ＨＤＬ，（ＴＣ－ＨＤＬ）／ＨＤＬ代谢紊乱的总有效率为９３．３％，６６．６％，２３．３％，８３．３％；辛伐他汀组的总有效率分别为９０．３％，８３．９％，３５．５％，９０．３％。两组间上述参数在治疗前、治疗后４周和６周均无明显统计学差异（Ｐ＞０．０５）。结论：洛之达调节血脂代谢紊乱疗效与辛伐他汀疗效基本相当
OBJECTIVE: To compare the clinical effects of lovastatin (domestic lovastatin) and simvastatin in regulating dyslipidemia. Methods: Sixty-one patients with primary dyslipidemia were selected and randomly divided into losartan (20 mg / d) and simvastatin (10 mg / d) control group (n = 31) for 6 weeks. Results: Compared with pretreatment, Losartan treatment for 6 weeks reduced the levels of TC, LDL-C and ApoB by 35.1%, 37.7% and 15.6%, respectively, while the simvastatin group was significantly different A decrease of 38.7%, 42.7% and 16.7% respectively. The total effective rate of Losartan in the regulation of TC, TG, HDL, (TC-HDL) / HDL metabolic disorders was 93.3%, 66.6%, 23.3%, 83.3% The effective rates were 90.3%, 83.9%, 35.5% and 90.3% respectively. The above parameters between the two groups before treatment, 4 weeks and 6 weeks after treatment no significant difference (P> 0.05). Conclusion: Losedol regulates the dyslipidemia efficacy and simvastatin efficacy is basically the same